Tune Therapeutics
Durham and Seattle, US · Founded 2020 · Delaware corporation · 64 employees on LinkedIn · 7 known investors
Find your way into Tune Therapeutics
517 people in our graph share verified history with the Tune Therapeutics team — schools, employers, funds. One of them is your warm intro.
Sam Blackmanunlockedknows Blythe Sather · together at Juno Therapeutics, Inc. (overlapped)
×2knows the team · via University of Colorado Boulder
×4knows the team · via Duke University
knows the team · via Assemblybio
knows the team · via University of Melbourne
×2knows the team · via The Johns Hopkins University School of Medicine
Tune Therapeutics develops a therapeutic platform targeting the epigenome to treat complex diseases and regenerative medicine applications. The company works on novel gene network therapies for challenging diseases.
Founders & leadership
Tune Therapeutics was founded in 2020 by Akira Matsuno, Derek Jantz, and Charles Gersbach.
AM
Akira MatsunoinCo-Founder, President, COO & CFO
DJ
Derek JantzinCo-founder · Chief Scientific OfficerDerek Jantz has led biotech research teams and developed gene and cell therapies from concept to early clinical stages. He was a co-founder of Precision BioSciences and has directed therapeutic programs that entered clinical trials for gene-edited therapies.
CG
Charles GersbachinCo-Founder, Director, Scientific AdvisorHe has expertise in genome engineering, synthetic biology, and gene and cell therapy.
JM
John McHutchisoninCEO, Chairman of the BoardJohn McHutchison is CEO and Chairman of Tune Therapeutics, which develops epigenome editing therapies for complex diseases and regenerative medicine applications.
DM
Dan McHughinInterim CEO2024–2025
BS
Blythe SatherinSenior Vice President ResearchBlythe Sather is a research executive with over 25 years of experience in immunology and cell therapy development. At Juno and Lyell Immunopharma, she built teams that designed CAR-T and TCR therapies now in clinical testing; she currently leads research at Tune Therapeutics on epigenetic editing approaches for gene and cell therapies.
YZ
Yuan ZhangExecutive
ZH
Zachary HaleinEVP, General Counsel
Board
AB
Investors · 7
Duke Capital PartnersDurham
Hatteras Venture PartnersResearch Triangle · $500K – $4M
Mission BiocapitalSan Francisco · $500K
New Enterprise Associates (NEA)Menlo Park · $200K – $40Mvia Ali Behbahani · board
Yosemitereported · 2 sourcesSan Francisco
Also in the syndicate · 2
Hevolution FoundationleadRegeneron Ventureslead
Funding
SEC filings, press & company announcements$357.4M disclosed across 2 rounds · 2023–2025
- $175MSeries BJan 2025 · 3 sources
Hevolution Foundation (lead), New Enterprise Associates (lead), Regeneron Ventures (lead), Yosemite (lead)
Source ↗
▶$182.4MraisedJan 2025 · 39 investors · BiotechnologyRule 506(b)
▶$182.4MraisedJan 2025 · 39 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Dan McHughExecutive Officer, Director
- Akira MatsunoExecutive Officer
- Blythe SatherExecutive Officer
- Derek JantzExecutive Officer
- Charles GersbachDirector
- John McHutchisonDirector
- Yuan ZhangExecutive Officer
- Zachary HaleExecutive Officer
- Ali BehbahaniDirector
- Offering amount
- $208M
- Amount sold
- $182.4M
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through Tune Therapeutics went on to found or lead other companies.
In the news
Frequently asked questions
- What does Tune Therapeutics do?
- Tune Therapeutics develops a therapeutic platform targeting the epigenome to treat complex diseases and regenerative medicine applications. The company works on novel gene network therapies for challenging diseases.
- Who founded Tune Therapeutics?
- Tune Therapeutics was founded by Akira Matsuno, Derek Jantz, Charles Gersbach in 2020.
- Who are Tune Therapeutics's investors?
- Tune Therapeutics's investors include Duke Capital Partners, Hatteras Venture Partners, Mission Biocapital, New Enterprise Associates (NEA), Yosemite.
- How much funding has Tune Therapeutics raised?
- Tune Therapeutics has disclosed $357.4M raised across 2 rounds.
- Where is Tune Therapeutics headquartered?
- Tune Therapeutics is headquartered in Durham and Seattle, US.